Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU group.
Bouffioux
C
C
Department of Urology, University Hospital Liège, Belgium.
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001500:BCG Vaccine / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D015201:Meta-Analysis as Topic; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine